Abstract
Gliomas are one of the most prevalent malignant brain tumors. Hence, identifying biological markers for glioma is imperative.(Tetratricopeptide Repeat Domain 7B) is a gene whose role in cancer in currently identified. To this end, we examined theexpression as well as its prognostic significance, biological roles, and immune system impacts in patients with glioma. We evaluated the function ofin GBM and LGG through the published CGGA (Chinese Glioma Genome Atlas) and TCGA (The Cancer Genome Atlas) databases. CIBERSORT and TIMER were used to analyze the link betweenand immune cells, while R was used for statistical analysis. In addition, Transwell analysis, including migration and invasion assays, was performed to identify the relationship betweenand temozolomide. Low expression ofwas observed in GBM and LGG. 1p/19q codeletion,mutation, chemotherapy, and grade were found to have a significant correlation with. Besides, lowexpression was linked with low overall survival (OS) in both GBM and LGG. In the Cox analysis,was found to independently function as a risk element for OS of patients with glioma. Furthermore, CIBERSORT analysis demonstrated a positive link betweenand multiple immune cells, especially activated NK cells. Transwell analysis, including migration and invasion assays, revealed that temozolomide reduced the migration and invasion capacity of glioma cells and increased the expression of. In all,could serve as a promising prognostic indicator of LGG and GBM, and is closely associated with immune infiltration and response to oxidative stress by temozolomide.
Overview
- The study aims to investigate the expression and prognostic significance of Tetratricopeptide Repeat Domain 7B (TTRD7B) in patients with glioma. The study evaluates the function of TTRD7B in GBM and LGG through the published CGGA and TCGA databases. CIBERSORT and TIMER were used to analyze the link between TTRD7B and immune cells, while R was used for statistical analysis. Transwell analysis, including migration and invasion assays, was performed to identify the relationship between TTRD7B and temozolomide. The study finds that low expression of TTRD7B is associated with low overall survival in both GBM and LGG. In the Cox analysis, TTRD7B is found to independently function as a risk element for OS of patients with glioma. Furthermore, CIBERSORT analysis demonstrates a positive link between TTRD7B and multiple immune cells, especially activated NK cells. Transwell analysis reveals that temozolomide reduces the migration and invasion capacity of glioma cells and increases the expression of TTRD7B. Overall, TTRD7B could serve as a promising prognostic indicator of LGG and GBM, and is closely associated with immune infiltration and response to oxidative stress by temozolomide.
Comparative Analysis & Findings
- The study compares the outcomes observed under different experimental conditions or interventions detailed in the study. The study finds that low expression of TTRD7B is associated with low overall survival in both GBM and LGG. In the Cox analysis, TTRD7B is found to independently function as a risk element for OS of patients with glioma. Furthermore, CIBERSORT analysis demonstrates a positive link between TTRD7B and multiple immune cells, especially activated NK cells. Transwell analysis reveals that temozolomide reduces the migration and invasion capacity of glioma cells and increases the expression of TTRD7B. Overall, the study identifies TTRD7B as a promising prognostic indicator of LGG and GBM, and is closely associated with immune infiltration and response to oxidative stress by temozolomide.
Implications and Future Directions
- The study's findings suggest that TTRD7B could serve as a promising prognostic indicator of LGG and GBM, and is closely associated with immune infiltration and response to oxidative stress by temozolomide. The study identifies TTRD7B as a potential target for the development of new therapies for glioma. Future research directions could focus on validating the prognostic significance of TTRD7B in larger cohorts and exploring its role in the immune response to temozolomide. Additionally, future research could investigate the potential therapeutic benefits of targeting TTRD7B in glioma.